Saveria Femminò

Dr. Saveria Femminò

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2018 in Basic Research in Cardiology
Verified
Journal Article
Open access
PDF file
HBHans Erik Bøtker
Hans Erik Bøtker
DHDerek Hausenloy
Derek Hausenloy
IAIoanna Andreadou
Ioanna Andreadou
SASalvatore Antonucci
Salvatore Antonucci
KBKerstin Boengler
Kerstin Boengler
GHGerd Heusch
Gerd Heusch

1 January 2016 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
Raffaella MastrocolaRaffaella Mastrocola
Raffaella Mastrocola
CPClaudia Penna
Claudia Penna
FTFrancesca Tullio
Francesca Tullio
SFSaveria Femminò
Saveria Femminò
DNDebora Nigro
Debora Nigro
Massimo CollinoMassimo Collino
Massimo Collino
Although the nucleotide‐binding oligomerization domain‐ (NOD‐) like receptor pyrin domain containing 3 (NLRP3) inflammasome has been recently detected in the heart, its role in cardiac ischemia/reperfusion (IR) is still controversial. Here, we investigate whether a pharmacological modulation of NLRP3 inflammasome exerted protective effects in an ex vivo model of IR injury. Isolated hearts from male Wistar rats (5‐6 months old) underwent ischemia (30 min) followed by reperfusion (20 or 60 min) with and without pretreatment with the recently synthetized NLRP3 inflammasome inhibitor INF4E (50 μM, 20 min before ischemia). INF4E exerted protection against myocardial IR, shown by a significant reduction in infarct size and lactate dehydrogenase release and improvement in postischemic left ventricular pressure. The formation of the NLRP3 inflammasome complex was induced by myocardial IR and attenuated by INF4E in a time‐dependent way. Interestingly, the hearts of the INF4E‐pretreated animals displayed a marked improvement of the protective RISK pathway and this effect was associated increase in expression of markers of mitochondrial oxidative phosphorylation. Our results demonstrate for the first time that INF4E protected against the IR‐induced myocardial injury and dysfunction, by a mechanism that involves inhibition of the NLRP3 inflammasome, resulting in the activation of the prosurvival RISK pathway and improvement in mitochondrial function.

3 May 2019 in Antioxidants & Redox Signaling
Verified
Journal Article
Open access
CTCarlo Gabriele Tocchetti
Carlo Gabriele Tocchetti
CCChristian Cadeddu
Christian Cadeddu
DLDaniela Di Lisi
Daniela Di Lisi
SFSaveria Femminò
Saveria Femminò
RMRosalinda Madonna
Rosalinda Madonna
GMGiuseppe Mercuro
Giuseppe Mercuro
Significance: Antineoplastic therapies have significantly improved the prognosis of oncology patients. However, these treatments can bring to a higher incidence of side-effects, including the worrying cardiovascular toxicity (CTX). Recent Advances: Substantial evidence indicates multiple mechanisms of CTX, with redox mechanisms playing a key role. Recent data singled out mitochondria as key targets for antineoplastic drug-induced CTX; understanding the underlying mechanisms is, therefore, crucial for effective cardioprotection, without compromising the efficacy of anti-cancer treatments. Critical Issues: CTX can occur within a few days or many years after treatment. Type I CTX is associated with irreversible cardiac cell injury, and it is typically caused by anthracyclines and traditional chemotherapeutics. Type II CTX is generally caused by novel biologics and more targeted drugs, and it is associated with reversible myocardial dysfunction. Therefore, patients undergoing anti-cancer treatments should be closely monitored, and patients at risk of CTX should be identified before beginning treatment to reduce CTX-related morbidity. Future Directions: Genetic profiling of clinical risk factors and an integrated approach using molecular, imaging, and clinical data may allow the recognition of patients who are at a high risk of developing chemotherapy-related CTX, and it may suggest methodologies to limit damage in a wider range of patients. The involvement of redox mechanisms in cancer biology and anticancer treatments is a very active field of research. Further investigations will be necessary to uncover the hallmarks of cancer from a redox perspective and to develop more efficacious antineoplastic therapies that also spare the cardiovascular system.

1 December 2020 in Vascular Pharmacology
Verified
Journal Article
Closed access
SFSaveria Femminò
Saveria Femminò
CPClaudia Penna
Claudia Penna
SMSara Margarita
Sara Margarita
SCStefano Comità
Stefano Comità
MBMaria F. Brizzi
Maria F. Brizzi
Pasquale PagliaroPasquale Pagliaro
Pasquale Pagliaro

1 January 2020 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
FFFederico Figliolini
Federico Figliolini
ARAndrea Ranghino
Andrea Ranghino
Cristina GrangeCristina Grange
Cristina Grange
MCMassimo Cedrino
Massimo Cedrino
MTMarta Tapparo
Marta Tapparo
MBMaria Felice Brizzi
Maria Felice Brizzi
Objectives: Critical hindlimb ischemia is a severe consequence of peripheral artery disease. Surgical treatment does not prevent skeletal muscle impairment or improve long-term patient outcomes. The present study investigates the protective/regenerative potential and the mechanism of action of adipose stem cell-derived extracellular vesicles (ASC-EVs) in a mouse model of hindlimb ischemia. Approach and Results: We demonstrated that ASC-EVs exert a protective effect on muscle damage by acting both on tissue microvessels and muscle cells. The genes involved in muscle regeneration were up-regulated in the ischemic muscles of ASC-EV-treated animals. MyoD expression has also been confirmed in satellite cells. This was followed by a reduction in muscle function impairment in vivo. ASC-EVs drive myoblast proliferation and differentiation in the in vitro ischemia/reoxygenation model. Moreover, ASC-EVs have shown an anti-apoptotic effect both in vitro and in vivo. Transcriptomic analyses have revealed that ASC-EVs carry a variety of pro-angiogenic mRNAs, while proteomic analyses have demonstrated an enrichment of NRG1 (neuregulin 1). A NRG1 blocking antibody used in vivo demonstrated that NRG1 is relevant to ASC-EV-induced muscle protection, vascular growth, and recruitment of inflammatory cells. Finally, bioinformatic analyses on 18 molecules that were commonly detected in ASC-EVs, including mRNAs and proteins, confirmed the enrichment of pathways involved in vascular growth and muscle regeneration/protection. Conclusions: This study demonstrates that ASC-EVs display pro-angiogenic and skeletal muscle protective properties that are associated with their NRG1/mRNA cargo. We, therefore, propose that ASC-EVs are a useful tool for therapeutic angiogenesis and muscle protection.

26 July 2017 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
CPClaudia Penna
Claudia Penna
FTFrancesca Tullio
Francesca Tullio
SFSaveria Femminò
Saveria Femminò
Carmine RoccaCarmine Rocca
Carmine Rocca
Tommaso AngeloneTommaso Angelone
Tommaso Angelone
Riccarda GranataRiccarda Granata
Riccarda Granata
Patients with ischaemic heart disease or chronic heart failure show altered levels of obestatin, suggesting a role for this peptide in human heart function. We have previously demonstrated that GH secretagogues and the ghrelin gene‐derived peptides, including obestatin, exert cardiovascular effects by modulating cardiac inotropism and vascular tone, and reducing cell death and contractile dysfunction in hearts subjected to ischaemia/reperfusion (I/R), through the Akt/nitric oxide (NO) pathway. However, the mechanisms underlying the cardiac actions of obestatin remain largely unknown. Thus, we suggested that obestatin‐induced activation of PI3K/Akt/NO and PKG signalling is implicated in protection of the myocardium when challenged by adrenergic, endothelinergic or I/R stress. We show that obestatin exerts an inhibitory tone on the performance of rat papillary muscle in both basal conditions and under β‐adrenergic overstimulation, through endothelial‐dependent NO/cGMP/PKG signalling. This pathway was also involved in the vasodilator effect of the peptide, used both alone and under stress induced by endothelin‐1. Moreover, when infused during early reperfusion, obestatin reduced infarct size in isolated I/R rat hearts, through an NO/PKG pathway, comprising ROS/PKC signalling, and converging on mitochondrial ATP‐sensitive potassium [mitoK(ATP)] channels. Overall, our results suggest that obestatin regulates cardiovascular function in stress conditions and induces cardioprotection by mechanisms dependent on activation of an NO/soluble guanylate cyclase (sGC)/PKG pathway. In fact, obestatin counteracts exaggerated β‐adrenergic and endothelin‐1 activity, relevant factors in heart failure, suggesting multiple positive effects of the peptide, including the lowering of cardiac afterload, thus representing a potential candidate in pharmacological post‐conditioning.